

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the quarterly period ended **December 31, 2022**

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: **001-33216**

**SONOMA PHARMACEUTICALS, INC.**  
(Name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of Incorporation or Organization)

**68-0423298**  
(I.R.S. Employer identification No.)

**5445 Conestoga Court, Suite 150, Boulder, CO**  
(Address of principal executive offices)

**80301**  
(Zip Code)

**(800) 759-9305**  
(Registrant's telephone number, including area code)

**N/A**  
(Former name or former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of Each Class</u>	<u>Trading Symbol</u>	<u>Name of Each Exchange on Which Registered</u>
Common Stock, \$0.0001 par value	SNOA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer <input type="checkbox"/>	Accelerated filer <input type="checkbox"/>
Non-accelerated filer <input checked="" type="checkbox"/>	Smaller reporting company <input checked="" type="checkbox"/>
Emerging Growth Company <input type="checkbox"/>	

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the registrant's common stock, par value \$0.0001 per share, as of February 10, 2023 was 4,649,247.

---

SONOMA PHARMACEUTICALS, INC.

Index

	<u>Page</u>
<b><u>PART I - FINANCIAL INFORMATION</u></b>	3
Item 1. <u>Unaudited Financial Statements</u>	3
<u>Condensed Consolidated Balance Sheets</u>	3
<u>Condensed Consolidated Statements of Comprehensive Income (Loss)</u>	4
<u>Condensed Consolidated Statements of Cash Flows</u>	5
<u>Condensed Consolidated Statements of Changes in Stockholders' Equity</u>	6
<u>Notes to Condensed Consolidated Financial Statements</u>	7
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	16
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	26
Item 4. <u>Controls and Procedures</u>	26
 <b><u>PART II - OTHER INFORMATION</u></b>	 28
Item 1. <u>Legal Proceedings</u>	28
Item 1A. <u>Risk Factors</u>	28
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	28
Item 3. <u>Defaults Upon Senior Securities</u>	28
Item 4. <u>Mine Safety Disclosures</u>	28
Item 5. <u>Other Information</u>	28
Item 6. <u>Exhibits</u>	29
<u>Signatures</u>	33

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Balance Sheets**  
(In thousands, except share amounts)

	<b>December 31, 2022</b>	<b>March 31, 2022</b>
<b>ASSETS</b>	<b>(Unaudited)</b>	
Current assets:		
Cash and cash equivalents	\$ 2,634	\$ 7,396
Accounts receivable, net	2,297	2,407
Inventories, net	2,849	2,663
Prepaid expenses and other current assets	3,230	3,746
Current portion of deferred consideration, net of discount	222	218
Total current assets	<u>11,232</u>	<u>16,430</u>
Property and equipment, net	314	320
Operating lease, right of use assets	471	559
Deferred tax asset	1,089	829
Deferred consideration, net of discount, less current portion	514	630
Other assets	308	77
Total assets	<u>\$ 13,928</u>	<u>\$ 18,845</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 1,302	\$ 1,641
Accrued expenses and other current liabilities	2,201	1,843
Deferred revenue	100	1,223
Deferred revenue Invekra	55	54
Current portion of debt-PPP	—	120
Short-term debt	—	688
Operating lease liabilities	276	250
Total current liabilities	<u>3,934</u>	<u>5,819</u>
Long-term deferred revenue Invekra	128	182
Long-term debt	15	—
Withholding tax payable	4,097	3,838
Operating lease liabilities, less current portion	195	309
Total liabilities	<u>8,369</u>	<u>10,148</u>
Commitments and Contingencies (Note 5)		
Stockholders' Equity:		
Convertible preferred stock, \$0.0001 par value; 714,286 shares authorized at December 31, 2022 and March 31, 2022, respectively, no shares issued and outstanding at December 31, 2022 and March 31, 2022, respectively	—	—
Common stock, \$0.0001 par value; 24,000,000 shares authorized at December 31, 2022 and March 31, 2022, respectively, 3,109,652 and 3,100,937 shares issued and outstanding at December 31, 2022 and March 31, 2022, respectively (Note 7)	2	2
Additional paid-in capital	197,939	197,370
Accumulated deficit	(188,206)	(184,363)
Accumulated other comprehensive loss	(4,176)	(4,312)
Total stockholders' equity	<u>5,559</u>	<u>8,697</u>
Total liabilities and stockholders' equity	<u>\$ 13,928</u>	<u>\$ 18,845</u>

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

**SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Statements of Comprehensive Income (Loss)**  
(In thousands, except per share amounts)  
(Unaudited)

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2022	2021	2022	2021
Revenues	\$ 2,944	\$ 2,902	\$ 10,258	\$ 10,330
Cost of revenues	2,113	1,699	6,645	6,433
Gross profit	831	1,203	3,613	3,897
Operating expenses				
Research and development	—	26	6	121
Selling, general and administrative	2,665	2,135	7,030	6,603
Total operating expenses	2,665	2,161	7,036	6,724
Loss from operations	(1,834)	(958)	(3,423)	(2,827)
Interest income (expense), net	1	3	4	(1)
Other income (expense), net	(73)	11	(327)	542
Gain on sale of assets	1	—	1	150
Loss before income taxes	(1,905)	(944)	(3,745)	(2,136)
Income tax benefit (expense)	(34)	—	(98)	(6)
Net loss	\$ (1,939)	\$ (944)	\$ (3,843)	\$ (2,142)
Net loss per share: basic	\$ (0.62)	\$ (0.31)	\$ (1.24)	\$ (0.85)
Net loss per share: diluted	\$ (0.62)	\$ (0.31)	\$ (1.24)	\$ (0.85)
Weighted-average number of shares: basic	3,107	3,080	3,104	2,507
Weighted-average number of shares: diluted	3,107	3,080	3,104	2,507
Other comprehensive loss				
Net loss	\$ (1,939)	\$ (944)	\$ (3,843)	\$ (2,142)
Foreign currency translation adjustments	235	(65)	136	8
Comprehensive loss	\$ (1,704)	\$ (1,009)	\$ (3,707)	\$ (2,134)

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

**SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Statements of Cash Flows**  
(In thousands)  
(Unaudited)

	<b>Nine Months Ended December 31,</b>	
	<b>2022</b>	<b>2021</b>
<b>Cash flows from operating activities</b>		
Net loss	\$ (3,843)	\$ (2,142)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	91	137
Forgiveness of PPP loan	—	(723)
Stock-based compensation	569	170
Gain on sale of assets	(1)	(150)
Changes in operating assets and liabilities:		
Accounts receivable	129	(58)
Inventories	(162)	(366)
Deferred consideration	129	(2)
Prepaid expenses and other current assets	572	114
Operating lease right-of-use assets	94	148
Accounts payable	(353)	(189)
Accrued expenses and other current liabilities	346	137
Deferred tax asset	(243)	—
Withholding tax payable	259	273
Operating lease liabilities	(94)	(145)
Deferred revenue	(1,204)	(57)
Net cash used in operating activities	(3,711)	(2,853)
<b>Cash flows from investing activities:</b>		
Purchases of property and equipment	(79)	(75)
Deposits	(97)	37
Net cash used in investing activities	(176)	(38)
<b>Cash flows from financing activities:</b>		
Proceeds from issuance of common stock, net of issuance costs	—	7,554
Proceeds from exercise of common stock options and purchase warrants	—	216
Payments on PPP Loan	(120)	—
Payments on offering costs	(89)	—
Principal payments on long-term debt	(674)	(596)
Net cash provided by (used in) financing activities	(883)	7,174
Effect of exchange rate on cash and cash equivalents	8	26
Net (decrease) increase in cash and cash equivalents	(4,762)	4,309
Cash and cash equivalents, beginning of period	7,396	4,220
Cash and cash equivalents, end of period	<u>\$ 2,634</u>	<u>\$ 8,529</u>
<b>Supplemental disclosure of cash flow information:</b>		
Cash paid for interest	<u>\$ 12</u>	<u>\$ 12</u>

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

**SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Statements of Changes in Stockholders' Equity**  
(In thousands, except share amounts)  
(Unaudited)

	Common Stock (\$0.0001 par Value)		Additional Paid in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
	Shares	Amount				
Balance March 31, 2022	3,100,937	\$ 2	\$ 197,370	\$ (184,363)	\$ (4,312)	\$ 8,697
Employee stock-based compensation expenses	—	—	214	—	—	214
Foreign currency translation adjustment	—	—	—	—	(65)	(65)
Net loss	—	—	—	(887)	—	(887)
Balance, June 30, 2022	3,100,937	\$ 2	\$ 197,584	\$ (185,250)	\$ (4,377)	\$ 7,959
Employee stock-based compensation expense	—	—	108	—	—	108
Stock based compensation related to issuance of restricted common stock	2,035	—	5	—	—	5
Foreign currency translation adjustment	—	—	—	—	(34)	(34)
Net loss	—	—	—	(1,017)	—	(1,017)
Balance, September 30, 2022	3,102,972	\$ 2	\$ 197,697	\$ (186,267)	\$ (4,411)	\$ 7,021
Employee stock-based compensation expense	—	—	233	—	—	233
Stock based compensation related to issuance of restricted common stock	6,680	—	9	—	—	9
Foreign currency translation adjustment	—	—	—	—	235	235
Net loss	—	—	—	(1,939)	—	(1,939)
Balance, December 31, 2022	3,109,652	\$ 2	\$ 197,939	\$ (188,206)	\$ (4,176)	\$ 5,559

  

	Common Stock (\$0.0001 par Value)		Additional Paid in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
	Shares	Amount				
Balance March 31, 2021	2,092,909	\$ 2	\$ 189,217	\$ (179,277)	\$ (4,579)	\$ 5,363
Transaction costs related to ATM agreement offering	—	—	(10)	—	—	(10)
Employee stock-based compensation expenses	—	—	56	—	—	56
Stock based compensation related to issuance of restricted common stock	—	—	3	—	—	3
Foreign currency translation adjustment	—	—	—	—	307	307
Net loss	—	—	—	(1,098)	—	(1,098)
Balance, June 30, 2021	2,092,909	\$ 2	\$ 189,266	\$ (180,375)	\$ (4,272)	\$ 4,621
Issuance of common stock in connection with ATM, net of transaction costs	855,500	1	6,901	—	—	6,902
Issuance of common stock due to options exercises	44,042	—	193	—	—	193
Issuance of common stock due to warrants exercises	12,290	—	23	—	—	23
Employee stock-based compensation expense	—	—	52	—	—	52
Stock based compensation related to issuance of restricted common stock	—	—	3	—	—	3
Foreign currency translation adjustment	—	—	—	—	(234)	(234)
Net loss	—	—	—	(100)	—	(100)
Balance, September 30, 2021	3,004,741	\$ 3	\$ 196,438	\$ (180,475)	\$ (4,506)	\$ 11,460
Shares issued in connection with ATM, net of transaction costs	94,600	—	662	—	—	662
Employee stock-based compensation expense	—	—	56	—	—	56
Foreign currency translation adjustment	—	—	—	—	(65)	(65)
Net loss	—	—	—	(944)	—	(944)
Balance, December 31, 2021	3,099,341	\$ 3	\$ 197,156	\$ (181,419)	\$ (4,571)	\$ 11,169

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

**SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES**  
**Notes to Condensed Consolidated Financial Statements**  
(Unaudited)

**Note 1.        Organization and Recent Developments**

***Organization***

Sonoma Pharmaceuticals, Inc. (the “Company”) was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware in December 2006. The Company’s principal office was moved to Woodstock, Georgia from Petaluma, California in June 2020, and to Boulder, Colorado in October 2022. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (“HOCl”) products for a wide range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. The Company’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The Company sells its products either directly or via partners in 55 countries worldwide.

***Basis of Presentation***

The accompanying unaudited condensed consolidated financial statements as of December 31, 2022 and for the nine months then ended have been prepared in accordance with the accounting principles generally accepted in the United States of America for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of December 31, 2022, the condensed consolidated statements of comprehensive income (loss) for the three and nine months ended December 31, 2022 and 2021, the cash flows for the nine months ended December 31, 2022 and 2021 and the condensed consolidated statement of stockholders’ equity for the three and nine months ended December 31, 2022 and 2021 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the consolidated financial position, operating results and cash flows for the periods presented. The results for the nine months ended December 31, 2022 are not necessarily indicative of results to be expected for the year ending March 31, 2023 or for any future interim period. The condensed consolidated balance sheet at March 31, 2022 has been derived from audited consolidated financial statements. These unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial information. Accordingly, they do not include all the information and notes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended March 31, 2022, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on July 13, 2022.

**Note 2.        Liquidity and Financial Condition**

The Company reported a net loss of \$1,939,000 and \$3,843,000 for the three and nine months ended December 31, 2022. At December 31, 2022 and March 31, 2022, the Company’s accumulated deficit amounted to \$188,206,000 and \$184,363,000, respectively. The Company had working capital of \$7,298,000 and \$10,611,000 as of December 31, 2022 and March 31, 2022, respectively. The cash balance at December 31, 2022 and March 31, 2022 was \$2,634,000 and \$7,396,000, respectively. Net cash used by operating activities during the nine months ended December 31, 2022 was \$3,711,000.

Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company's continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of the Company. These matters raise substantial doubt about the Company's ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.

**Note 3. Summary of Significant Accounting Policies**

***Use of Estimates***

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to the Company's deferred tax assets, valuation of equity and derivative instruments, and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.

***Net Loss per Share***

The following table provides the net loss for each period along with the computation of basic and diluted net loss per share:

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2022	2021	2022	2021
<i>(In thousands, except per share data)</i>				
Numerator:				
Net loss	\$ (1,939)	\$ (944)	\$ (3,843)	\$ (2,142)
Denominator:				
Weighted-average number of common shares outstanding: basic	3,107	3,080	3,104	2,507
Weighted-average number of common shares outstanding: diluted	3,107	3,080	3,104	2,507
Net loss per share: basic	\$ (0.62)	\$ (0.31)	\$ (1.24)	\$ (0.85)
Net loss per share: diluted	\$ (0.62)	\$ (0.31)	\$ (1.24)	\$ (0.85)



The computation of basic loss per share for the three and nine months ended December 31, 2022 and 2021 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2022	2021	2022	2021
<i>(In thousands)</i>				
Stock options	576	206	576	206
Warrants	108	106	108	106
Common stock units (1)	46	46	46	46
	<u>730</u>	<u>358</u>	<u>730</u>	<u>358</u>

(1) Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock

### **Revenue Recognition**

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”), Topic 606 Revenue from Contracts with Customers (“Topic 606”). Revenue is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.

The Company derives the majority of its revenue through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company also has entered into agreements to license its technology and products. The Company also provides regulatory compliance testing and quality assurance services to medical device and pharmaceutical companies.

The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled.

For all of its sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able to estimate the amount of product that will be returned. Sales incentives and other programs that the Company may make available to these customers are considered to be a form of variable consideration, and the Company maintains estimated accruals and allowances using the expected value method.

The Company has entered into consignment arrangements, in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company recognizes revenue based on a variable percentage of a fixed price. Revenue recognized varies depending on whether a patient is covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the Company's rebate program.

Sales to stocking distributors are made under terms with fixed pricing and limited rights of return (known as "stock rotation") of the Company's products held in their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.

The Company assessed the promised goods and services in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.

#### ***Accounts Receivable***

Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based on analysis of contractual terms and historical trends.

The Company's policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents probable credit losses of \$0 at December 31, 2022 and March 31, 2022. Additionally, at December 31, 2022 and March 31, 2022 the Company has allowances of \$33,000 and \$81,000 respectively, related to potential discounts, returns, distributor fees and rebates. The allowances are included in accounts receivable, net in the accompanying condensed consolidated balance sheets.

#### ***Inventories***

Inventories are stated at the lower of cost, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.

Due to changing market conditions, estimated future requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision to reduce the carrying amounts of inventories to their net realizable value in the amount of \$224,000 and \$218,000 at December 31, 2022 and March 31, 2022, respectively, which is included in cost of revenues on the Company's accompanying condensed consolidated statements of comprehensive income (loss).

#### ***Recent Accounting Standards***

Accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.

**Note 4. Condensed Consolidated Balance Sheet*****Inventories, net***

Inventories, net consist of the following:

	<b>December 31, 2022</b>	<b>March 31, 2022</b>
Raw materials	\$ 1,611,000	\$ 1,626,000
Finished goods	1,238,000	1,037,000
	<u>\$ 2,849,000</u>	<u>\$ 2,663,000</u>

***Leases***

The Company's operating leases are comprised primarily of facility leases. The Company did not have any finance leases as of December 31, 2022 and March 31, 2022. Balance sheet information related to our leases is presented below:

	<b>December 31, 2022</b>	<b>March 31, 2022</b>
<b>Operating leases:</b>		
Operating lease right-of-use assets	\$ 471,000	\$ 559,000
Operating lease liabilities – current	276,000	250,000
Operating lease liabilities – non-current	195,000	309,000

Other information related to leases is presented below:

**Nine Months Ended December 31, 2022**

Operating lease cost	279,000
Other information:	
Operating cash flows from operating leases	94,000
Weighted-average remaining lease term – operating leases (in months)	21.5
Weighted-average discount rate – operating leases	6.00%

As of December 31, 2022, the annual minimum lease payments of our operating lease liabilities were as follows:

**For Years Ending March 31,**

2023 (excluding the nine months ended December 31, 2022)	\$	82,000
2024		294,000
2025		143,000
2026		15,000
Total future minimum lease payments, undiscounted		534,000
Less: imputed interest		(63,000)
Present value of future minimum lease payments	\$	471,000

**Note 5. Commitments and Contingencies**

***Legal Matters***

The Company may be involved in legal matters arising in the ordinary course of business including matters involving proprietary technology. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its business and financial condition of comprehensive loss.

***Employment Agreements***

As of December 31, 2022, the Company had employment agreements in place with two of its key executives. These executive employment agreements provide, among other things, for the payment of up to twelve months of severance compensation for terminations under certain circumstances. With respect to these agreements, at December 31, 2022, aggregated annual salaries would be \$575,000 and potential severance payments to these key executives would be \$575,000 if triggered.

***Related Party Transactions***

Ms. Trombly was appointed the Chief Executive Officer of the Company. Ms. Trombly is the owner of Trombly Business Law, PC, which has been retained by the Company to advise on certain corporate and securities law matters. During the year ended March 31, 2022, the Company incurred \$170,000 in legal services from Trombly Business Law, PC. During the nine months ended December 31, 2022, the Company incurred \$27,000 in legal services from Trombly Business Law, PC. The Company ceased using Trombly Business Law, PC in July 2022.

**Note 6. Debt**

***Financing of Insurance Premiums***

On February 1, 2022, the Company entered into a note agreement for \$748,000 with an interest rate of 4.68% per annum with final payment due by January 1, 2023. This instrument was issued in connection with financing insurance premiums. The note is payable in ten monthly installment payments of principal and interest of \$76,000, with the first installment beginning March 1, 2022, and was fully paid as of December 31, 2022.

#### *Paycheck Protection Program Loan*

On May 1, 2020, the Company received loan proceeds in the amount of \$1,310,000 under the Paycheck Protection Program (“PPP”), from Coastal States Bank in Atlanta, Georgia. The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, (“CARES Act”), provided for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest were forgivable after eight or 24 weeks as long as the Company used the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains payroll levels. The amount of loan forgiveness was reduced if the Company terminated employees or reduced salaries during the applicable period.

The unsecured loan, which was in the form of a note dated April 29, 2020, matured on April 29, 2022 and bore interest at a rate of 1% per annum, payable monthly commencing on May 1, 2021. The note allowed for prepayment at any time prior to maturity with no prepayment penalties. The Company used the loan amount for eligible purposes, such as payroll expenses. The Company met the conditions for \$723,000 in forgiveness of the loan. As of December 31, 2022 the loan had been settled in full.

#### **Note 7. Stockholders’ Equity**

##### *Authorized Capital*

The Company is authorized to issue up to 24,000,000 shares of common stock with a par value of \$0.0001 per share and 714,286 shares of convertible preferred stock with a par value of \$0.0001 per share.

#### **Note 8. Stock-Based Compensation**

Stock-based compensation expense is as follows:

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2022	2021	2022	2021
<i>(In thousands)</i>				
Cost of revenues	\$ —	\$ —	\$ —	\$ —
Research and development	—	—	—	—
Selling, general and administrative	242	56	569	170
Total stock-based compensation	<u>\$ 242</u>	<u>\$ 56</u>	<u>\$ 569</u>	<u>\$ 170</u>

At December 31, 2022, there were unrecognized compensation costs of \$686,000 related to stock options, which is expected to be recognized over a weighted-average amortization period of 2.00 years.

Stock options award activity is as follows:

	Number of Shares	Weighted- Average Exercise Price
Outstanding at April 1, 2022	466,234	\$ 12.09
Options granted	191,082	1.11
Options exercised	—	—
Options forfeited	(58,165)	5.67
Options expired	(23,605)	19.24
Outstanding at December 31, 2022	575,546	\$ 8.80
Exercisable at December 31, 2022	214,626	\$ 18.28

The aggregate intrinsic value of stock options of zero is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company's common stock, or \$1.12 per share at December 31, 2022.

The Company did not capitalize any cost associated with stock-based compensation.

The Company issues new shares of common stock upon exercise of stock-based awards.

#### **Note 9. Income Taxes**

At the end of each interim reporting period, the Company determines the income tax provision by using an estimate of the annual effective tax rate, adjusted for discrete items occurring in the quarter.

Our effective tax rate for the nine months and three months ended December 31, 2022 was -2.69% and -1.68%. The Company's effective tax rate for the nine months and three months ended December 31, 2022 differed from the federal statutory tax rate of 21% primarily due to the valuation allowance recognized against deferred tax assets in the U.S. and permanent tax adjustment of intercompany interest expense in Mexico and Netherlands.

Judgment is required in determining whether deferred tax assets will be realized in full or in part. Management assesses the available positive and negative evidence on a jurisdictional basis to estimate if deferred tax assets will be recognized and when it is more likely than not that all or some deferred tax assets will not be realized, and a valuation allowance must be established. As of December 31, 2022, the Company continues to maintain a valuation allowance in U.S.

**Note 10. Revenue Disaggregation**

The Company generates revenues from products which are sold into the human and animal healthcare markets and to multiple geographic regions.

The following table presents the Company's disaggregated revenues by revenue source:

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2022	2021	2022	2021
<i>(In thousands)</i>				
Human Care	\$ 2,435	\$ 2,015	\$ 7,050	\$ 7,201
Animal Care	434	818	1,957	2,755
Service and Royalty	75	69	1,251	374
	<u>\$ 2,944</u>	<u>\$ 2,902</u>	<u>\$ 10,258</u>	<u>\$ 10,330</u>

The following table shows the Company's revenues by geographic region:

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2022	2021	2022	2021
<i>(In thousands)</i>				
United States	\$ 761	\$ 933	\$ 2,603	\$ 3,872
Europe	1,104	731	3,117	2,419
Asia	514	664	1,952	1,810
Latin America	384	273	1,827	1,356
Rest of the World	181	301	759	873
Total	<u>\$ 2,944</u>	<u>\$ 2,902</u>	<u>\$ 10,258</u>	<u>\$ 10,330</u>

**Note 11. Significant Customer Concentrations**

For the three months ended December 31, 2022, customer A represented 13%, customer B represented 11% and customer C represented 11% of net revenue. For the three months ended December 31, 2021, customer B represented 22% of net revenue. For the nine months ended December 31, 2022, customer A represented 18% of net revenue, customer B represented 16% and customer C represented 10% of net revenue. For the nine months ended December 31, 2021, customer B represented 23% of net revenue, and customer A represented 13% of net revenue.

At December 31, 2022, customer D represented 18%, customer B represented 12% and customer E represented 10% of the net accounts receivable balance. At March 31, 2022 customer A represented 20%, customer D represented 15%, and customer F represented 14% of the net accounts receivable balance.

**Note 12. Subsequent Events**At-The-Market Offering Agreement

On December 23, 2022, the Company entered into an At-The-Market Offering Agreement, or ATM Agreement, with Ladenburg Thalmann & Co. Inc., as sales agent, pursuant to which the Company may offer and sell, from time to time, through Ladenburg, shares of its common stock, \$0.0001 par value per share. The Company agreed to pay Ladenburg a commission of 3% of the aggregate gross proceeds from each sale of shares. From January 4, 2023 through February 2, 2023, the Company sold an aggregate of 1,535,718 shares of common stock for gross proceeds of \$2,699,906 and net proceeds of \$2,533,438 after deducting commissions and other offering expenses.

## **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q as of December 31, 2022 and our audited consolidated financial statements for the year ended March 31, 2022 included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on July 13, 2022.*

*This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this report, the words "anticipate," "suggest," "estimate," "plan," "project," "continue," "ongoing," "potential," "expect," "predict," "believe," "intend," "may," "will," "should," "could," "would," "proposal," and similar expressions are intended to identify forward-looking statements.*

*Forward-looking statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to the risks described in our Annual Report on Form 10-K including: the impact of the Covid pandemic on the overall economy and our results of operations; our ability to become profitable; the impact of changes to reimbursement levels from third-party payors or increased pricing pressure due to rebates; the impact of the Invektra transaction on our business and results of operations; our dependence on third-party distributors; certain tax impacts of inter-company loans between us and our Mexican subsidiary; the progress and timing of our development programs and regulatory approvals for our products; the benefits and effectiveness of our products; the ability of our products to meet existing or future regulatory standards; the progress and timing of clinical trials and physician studies; our expectations and capabilities relating to the sales and marketing of our current products and our product candidates; our ability to compete with other companies that are developing or selling products that are competitive with our products; the establishment of strategic partnerships for the development or sale of products; the risk our research and development efforts do not lead to new products; the timing of commercializing our products; our ability to penetrate markets through our sales force, distribution network, and strategic business partners to gain a foothold in the market and generate attractive margins; the ability to attain specified revenue goals within a specified time frame, if at all, or to reduce costs; the outcome of discussions with the U.S. Food and Drug Administration, or FDA, and other regulatory agencies; the content and timing of submissions to, and decisions made by, the FDA and other regulatory agencies, including demonstrating to the satisfaction of the FDA the safety and efficacy of our products; our ability to manufacture sufficient amounts of our products for commercialization activities; our ability to protect our intellectual property and operate our business without infringing on the intellectual property of others; our ability to continue to expand our intellectual property portfolio; the risk we may need to indemnify our distributors or other third parties; risks attendant with conducting a significant portion of our business outside the United States; our ability to comply with complex federal and state fraud and abuse laws, including state and federal anti-kickback laws; risks associated with changes to health care laws; our ability to attract and retain qualified directors, officers and employees; our expectations relating to the concentration of our revenue from international sales; our ability to expand to and commercialize products in markets outside the wound care market; our ability to protect our information technology and infrastructure; and the impact of any future changes in accounting regulations or practices in general with respect to public companies. These forward-looking statements speak only as of the date hereof. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, except as required by law.*

### **Our Business**

We are a global healthcare leader for developing and producing stabilized hypochlorous acid, or HOCl, products for a wide range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. Our products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Our stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated, assisting the body in its natural healing process.



## Business Channels

Our core market differentiation is based on being the leading developer and producer of stabilized hypochlorous acid, or HOCl, solutions. We have been in business for over 20 years, and in that time, we have developed significant scientific knowledge of how best to develop and manufacture HOCl products backed by decades of studies and data collection. HOCl is known to be among the safest and most-effective ways to relieve itch, inflammation and burns while stimulating natural healing through increased oxygenation and eliminating persistent microorganisms and biofilms.

We sell our products into many markets both in the U.S. and internationally. In international markets, we ship a variety of products to 55 countries. Our core strategy is to work with partners both in the United States and around the world to market and distribute our products. In some cases, we market and sell our own products.

### *Dermatology*

We have developed unique, differentiated, prescription-strength and safe dermatologic products that support paths to healing among various key dermatologic conditions. Our products are primarily targeted at the treatment of acne, the management of scars and eczema/atopic dermatitis. We are strategically focused on introducing innovative new products that are supported by human clinical data with applications that address specific dermatological procedures currently in demand. In addition, we look for markets where we can provide effective product line extensions and pricing to new product families.

In the United States, we partner with EMC Pharma, LLC to sell our prescription dermatology products. Pursuant to our agreement with EMC Pharma, we manufacture products for EMC Pharma and EMC Pharma has the right to market, sell and distribute them to patients and customers for an initial term of five years, subject to meeting minimum purchase and other requirements.

On September 28, 2021, we launched a new over-the-counter product, Regenacyn® Advanced Scar Gel, which is clinically proven to improve the overall appearance of scars while reducing pain, itch, redness, and inflammation. On the same day, we launched Regenacyn® Plus, a prescription-strength scar gel which is available as an office dispense product through physician offices.

On October 27, 2022, we launched two new over-the-counter dermatology products in the United States, Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel for the alleviation of red bumps, rashes, shallow skin fissures, peeling, and symptoms of eczema/atopic dermatitis, and Rejuvacyn® Advanced Skin Repair Cooling Mist for management of minor skin irritations following cosmetic procedures as well as daily skin health and hydration.

On January 4, 2023, we launched a line of office dispense products exclusively for skin care professionals, including two new prescription strength dermatology products, Reliefacyn® Plus Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn® Plus Skin Repair Cooling Mist. These products, along with Regenacyn® Plus Scar Gel, will be marketed and sold directly to dermatology practices and medical spas.

In June 2022, the Natural Products Association certified Rejuvacyn Advanced as a Natural Personal Care Product.

Our consumer products are available through Amazon.com, our website and third-party distributors.

We sell dermatology products in Europe, Asia, and Brazil through a distributor network. In these international markets, we have a network of partners, ranging from country specific distributors to large pharmaceutical companies to full-service sales and marketing companies. We work with our international partners to create products they can market in their home country. Some products we develop and manufacture are private label while others use branding we have already developed. We have created or co-developed a wide range of products for international markets using our core HOCl technology.

### *First Aid and Wound Care*

Our HOCl-based wound care products are intended for the treatment of acute and chronic wounds as well as first- and second-degree burns. They work by first removing foreign material and debris from the skin surface and moistening the skin, thereby improving wound healing. Second, our HOCl products assist in the wound healing process by removing microorganisms. Since HOCl is an important constituent of our innate immune system and is formed and released by the macrophages during phagocytosis, it is advantageous to other wound-irrigation and antiseptic solutions, as highly organized cell structures such as human tissue can tolerate the action of our wound care solution while single-celled microorganisms cannot. Due to its unique chemistry, our wound treatment solution is much more stable than similar products on the market and therefore maintains much higher levels of hypochlorous acid over its shelf life.

In the United States, we sell our wound care products directly to hospitals, physicians, nurses, and other healthcare practitioners and indirectly through non-exclusive distribution arrangements. In Europe, we sell our wound care products through a diverse network of distributors.

To respond to market demand for our HOCl technology-based products, we launched our first direct to consumer over-the-counter product in the United States in February 2021. Microcyn® OTC Wound and Skin Cleanser is formulated for home use without prescription to help manage and cleanse wounds, minor cuts, and burns, including sunburns and other skin irritations. Microcyn OTC is available without prescription through Amazon.com, our online store and third-party distributors.

In March 2021, we received approval to market and use our HOCl products as biocides under Article 95 of the European Biocidal Products Regulation in France, Germany and Portugal. The approval applies to our products MucoClyns™ for human hygiene to be marketed and commercialized by us, MicrocynAH® for animal health marketed and commercialized through our partner, Petagon Limited, and MicroSafe for disinfectant use to be marketed and commercialized through our partner, MicroSafe Group DMCC.

In June 2022, the Natural Products Association certified Microcyn OTC as a Natural Personal Care Product in the United States.

In September 2022, our partner Te Arai BioFarma Ltd. received approval to market and sell our Microdacyn and Microdacyn Hydrogel products in Taiwan.

### *Eye Care*

Our prescription product Acucyn™ is an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes and helps manage red, itchy, crusty and inflamed eyes. It is strong enough to kill the bacteria that causes discomfort, fast enough to provide near instant relief, and gentle enough to use as often as needed. In the United States, our partner EMC Pharma is selling our prescription-based eye care product through its distribution network.

On September 28, 2021, we launched Ocucyn® Eyelid & Eyelash Cleanser, which is sold directly to consumers on Amazon.com, through our online store, and through third party distributors. Ocucyn® Eyelid & Eyelash Cleanser, designed for everyday use, is a safe, gentle, and effective solution for good eyelid and eyelash hygiene.

In international markets we rely on distribution partners to sell our eye products. On May 19, 2020, we entered into an expanded license and distribution agreement with our existing partner, Brill International S.L. for our Microdacyn60® Eye Care HOCl-based product. Under the license and distribution agreement, Brill has the right to market and distribute our eye care product under the private label Ocudox™ in Italy, Germany, Spain, Portugal, France, and the United Kingdom for a period of 10 years, subject to meeting annual minimum sales quantities. In return, Brill paid us a one-time fee, and the agreed upon supply prices. In parts of Asia, Dyamed Biotech markets our eye product under the private label Ocucyn.

### *Oral, Dental and Nasal Care*

We sell a variety of oral, dental, and nasal products around the world.

In late 2020, we launched a HOCl-based product in the dental, head and neck markets called Endocyn®, a biocompatible root canal irrigant. In the U.S., we sell our dental products through U.S.-based distributors.

In international markets, our product Microdacyn60® Oral Care treats mouth and throat infections and thrush. Microdacyn60 solution assists in reducing inflammation and pain, provides soothing cough relief and does not contain any harmful chemicals. It does not stain teeth, is non-irritating, non-sensitizing, has no contraindications and is ready for use with no mixing or dilution. In New Zealand and Australia, our partner Te Arai BioFarma Ltd. markets our oral product under their label Oracyn® Oral Care. Our partner, Dyamed Biotech, is seeking regulatory clearance to market Oracyn® Oral Care in parts of Asia. On January 18, 2022, we partnered with Anlicare International to seek regulatory clearances for our dental and oral products in China and Macau.

Our international nasal care product Sinudox™ based on our HOCl technology is intended for nasal irrigation. Sinudox Hypotonic Nasal Hygiene clears and cleans a blocked nose, stuffy nose and sinuses by ancillary ingredients that may have a local antimicrobial effect. Sinudox is sold through Amazon in Europe. In New Zealand and Australia, our partner Te Arai markets our nasal product under their label Nasocyn® Nasal Care.

### *Animal Health Care*

MicrocynAH® is a HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections. It is intended for the safe and rapid treatment of a variety of animal afflictions including cuts, burns, lacerations, rashes, hot spots, rain rot, post-surgical sites, pink eye symptoms and wounds to the outer ear of any animal.

For our animal health products sold in the U.S. and Canada, we partnered with Manna Pro Products, LLC to bring relief to pets and peace of mind to their owners. Manna Pro distributes non-prescription products to national pet-store retail chains, farm animal specialty stores, in the United States and Canada, such as Chewy.com, PetSmart, Tractor Supply, Cabela's, PetExpress, and Bass Pro Shops. On August 2, 2022, we announced the launch of a MicrocynVS® line of products exclusively for veterinarians for the management of wound, skin, ear and eye afflictions in all animal species. We granted DV Medical Supply Inc. the non-exclusive right to distribute and sell MicrocynVS products in veterinarian clinics and practices throughout the United States.

For the Asian and European markets, on May 20, 2019, we partnered with Petagon, Limited, an international importer and distributor of quality pet food and products for an initial term of five years. We supply Petagon with all MicrocynAH products sold by Petagon. On August 3, 2020, Petagon received a license from the People's Republic of China for the import of veterinary drug products manufactured by us. This is the highest classification Petagon and Sonoma can receive for animal health products in China.

### *Surface Disinfectants*

In-vitro and clinical studies of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. HOCl has been formulated as a disinfectant and sanitizer solution for our partner MicroSafe and is sold in numerous countries. It is designed to be used to spray in aerosol format in areas and environments likely to serve as a breeding ground for the spread of infectious disease, which could result in epidemics or pandemics. The medical-grade surface disinfectant solution is used in hospitals worldwide to protect doctors and patients. In May 2020, Nanocyn® Disinfectant & Sanitizer received approval to be entered into the Australian Register of Therapeutic Goods, or ARTG for use against the coronavirus SARS-CoV-2, or COVID-19, and was also authorized in Canada for use against COVID-19. Nanocyn has also met the stringent environmental health and social/ethical criteria of Good Environmental Choice Australia, or GECA, becoming one of the very few eco-certified, all-natural disinfectant solutions in Australia.

Through our partner MicroSafe, we sell hard surface disinfectant products into Europe, the Middle East and Australia.

On July 31, 2021, we granted MicroSafe the non-exclusive right to sell and distribute Nanocyn in the United States provided that MicroSafe secure U.S. EPA approval. In April of 2022, MicroSafe secured the EPA approval for Nanocyn® Disinfectant & Sanitizer, meaning that it can now be sold in the United States as a surface disinfectant, and it was subsequently added to the EPA's list N for use against COVID-19. In June 2022, the EPA added Nanocyn to List Q as a disinfectant for Emerging Viral Pathogens, including Mpox. We intend to build upon this ground-breaking approval by securing further approvals of this nature. Nanocyn is a hospital-grade disinfectant and manufactured by us using our patented HOCl technology. Nanocyn is currently sold by MicroSafe in Europe, the Middle East and Australia.

#### Additional Information

Investors and others should note that we announce material financial information using our company website (www.sonomapharma.com), our investor relations website (ir.sonomapharma.com), SEC filings, press releases, public conference calls and webcasts. The information on, or accessible through, our websites is not incorporated by reference in this Quarterly Report on Form 10-Q.

#### Results of Continuing Operations

##### Comparison of the Three and Nine Months Ended December 31, 2022 and 2021

#### Revenue

The following table shows our consolidated total revenue and revenue by geographic region for the three and nine months ended December 31, 2022 and 2021:

	Three Months Ended December 31,		\$ Change	% Change
	2022	2021		
<i>(In thousands)</i>				
United States	\$ 761	\$ 933	\$ (172)	(18%)
Europe	1,104	731	373	51%
Asia	514	664	(150)	(23%)
Latin America	384	273	111	41%
Rest of the World	181	301	(120)	(40%)
Total	<u>\$ 2,944</u>	<u>\$ 2,902</u>	<u>\$ 42</u>	<u>1%</u>
	Nine Months Ended December 31,		\$ Change	% Change
	2022	2021		
<i>(In thousands)</i>				
United States	\$ 2,603	\$ 3,872	\$ (1,269)	(33%)
Europe	3,117	2,419	698	29%
Asia	1,952	1,810	142	8%
Latin America	1,827	1,356	471	35%
Rest of the World	759	873	(114)	(13%)
Total	<u>\$ 10,258</u>	<u>\$ 10,330</u>	<u>\$ (72)</u>	<u>(1%)</u>

The decrease in United States revenues of \$1,269,000 for the nine months ended December 31, 2022 compared to the same period in the prior year is primarily the result of transitioning our prescription dermatology business to our partner, EMC Pharma. Converting our prescription dermatology business to a distribution model resulted in a reduction of revenues, however we also eliminated significant expenses related to that line of products including a direct sales force. The decrease is also partially due to a decline in sales of our over-the-counter animal health care products and an overall retail market slowdown. The decrease in United States revenues of \$172,000 for the three months ended December 31, 2022 compared to the same period in the prior year is due to a decline in sales of our over-the-counter animal health care products and an overall retail market slowdown.

The increase in Europe revenue for the three and nine months ended December 31, 2022 was caused by an increase in demand for our wound care products as well as the introduction of several new products into Europe.

The decrease in Asia revenue for the three months and the increase for the nine months ended December 31, 2022 is due to lumpiness in ordering with increased orders in the first quarters and lower orders in the second quarter. Revenues from our international distributors tend to be choppy due to customers placing larger but less frequent orders to benefit from quantity discounts and reduced shipping costs when ordering sufficient quantities to fill standard sized shipping containers.

The increase in Latin America revenue for the three months ended December 31, 2022 was caused by timing of orders coming in later in 2022 compared to same quarter 2021. The increase in Latin America revenue for the nine months ended December 31, 2022 was primarily the result of service revenue from selling machinery to a customer for \$750,000, which management expects to be a one-time event. The increase was partially offset by a decline in manufacturing for one of our customers.

The decrease in Rest of World revenue for the three and nine months ended December 31, 2022 was primarily the result of decreased disinfectant sales in the Middle East partially offset by an increase in sales in India.

### **Cost of Revenue and Gross Profit**

The cost of revenue and gross profit metrics for the three and nine months ended December 31, 2022 and 2021 are as follows:

	<b>Three Months Ended December 31,</b>		<b>Change</b>	<b>% Change</b>
	<b>2022</b>	<b>2021</b>		
<i>(In thousands, except for percentages)</i>				
Cost of Revenue	\$ 2,113	\$ 1,699	\$ 414	24%
Cost of Revenue as a % of Revenue	72%	59%	13%	
Gross Profit	\$ 831	\$ 1,203	\$ (372)	(31%)
Gross Profit as a % of Revenue	28%	41%	(13%)	

  

	<b>Nine Months Ended December 31,</b>		<b>Change</b>	<b>% Change</b>
	<b>2022</b>	<b>2021</b>		
<i>(In thousands, except for percentages)</i>				
Cost of Revenue	\$ 6,645	\$ 6,433	\$ 212	3%
Cost of Revenue as a % of Revenue	65%	62%	3%	
Gross Profit	\$ 3,613	\$ 3,897	\$ (284)	(7%)
Gross Profit as a % of Revenue	35%	38%	(3%)	

The decrease in gross profit margin for the three months ended December 31, 2022 was primarily the result of lower manufacturing levels and higher costs of materials and transportation. The decrease in gross profit margin for the nine months ended December 31, 2022 was primarily due to higher costs of materials and transportation.

### Research and Development Expense

The research and development metrics for the three and nine months ended December 31, 2022 and 2021 are as follows:

	Three Months Ended December 31,		Change	% Change
	2022	2021		
<i>(In thousands, except for percentages)</i>				
Research and Development Expense	\$ —	\$ 26	\$ (26)	(100%)
Research and Development Expense as a % of Revenue	0%	1%	(1%)	

	Nine Months Ended December 31,		Change	% Change
	2022	2021		
<i>(In thousands, except for percentages)</i>				
Research and Development Expense	\$ 6	\$ 121	\$ (115)	(95%)
Research and Development Expense as a % of Revenue	0%	1%	(1%)	

For the three months ended December 31, 2022, research and development expenses decreased as a result of reduced clinical trial expense.

### Selling, General and Administrative Expense

The selling, general and administrative expense metrics are as follows:

	Three Months Ended December 31,		Change	% Change
	2022	2021		
<i>(In thousands, except for percentages)</i>				
Selling, General and Administrative Expense (SG&A)	\$ 2,665	\$ 2,135	\$ 530	25%
SG&A Expense as a % of Revenue	91%	74%	17%	

	Nine Months Ended December 31,		Change	% Change
	2022	2021		
<i>(In thousands, except for percentages)</i>				
Selling, General and Administrative Expense (SG&A)	\$ 7,030	\$ 6,603	\$ 427	6%
SG&A Expense as a % of Revenue	69%	64%	5%	

The increase in Selling, General and Administrative expense for the three and nine months ended December 31, 2022 was \$530,000 and \$427,000, respectively, and was the result of closing down our Woodstock, GA facility and moving finance and operations to our Boulder, CO headquarters. Management expects the expenses related to the consolidation of our Woodstock, GA office into our Boulder, CO office to be primarily one-time expenses. Additionally, the quarter ending December 31, 2022 included a settlement of a long-term contract that resulted in an additional \$350,000 of expenses recorded during the period. Management expects this to be a one-time event.

### ***Interest Income (Expense), net***

Interest (expense) income, net for the three and nine months ended December 31, 2022 was \$1,000 and \$4,000, respectively, compared to \$3,000, and \$(1,000) for the three and nine months ended December 31, 2021, respectively.

### ***Other (Expense) Income, net***

Other (expense) income for the three and nine months ended December 31, 2022 was \$(73,000) and \$(327,000) respectively, compared to \$11,000 and \$542,000, respectively, for the three and nine months ended December 31, 2021. The decrease in other income (expense) relates primarily to the recognition of PPP loan forgiveness in the amount of \$723,000 in the prior year and, to a lesser extent, to exchange rate fluctuations.

### ***Income taxes***

Income tax expense for the three and nine months ended December 31, 2022 was \$34,000 and \$98,000.

### ***Net Loss***

The following table provides the net loss for each period along with the computation of basic and diluted net loss per share:

	<b>Three Months Ended December 31,</b>		<b>Nine Months Ended December 31,</b>	
	<b>2022</b>	<b>2021</b>	<b>2022</b>	<b>2021</b>
<i>(In thousands, except per share data)</i>				
Numerator:				
Net loss	\$ (1,939)	\$ (944)	\$ (3,843)	\$ (2,142)
Denominator:				
Weighted-average number of common shares outstanding: basic	3,107	3,080	3,104	2,507
Weighted-average number of common shares outstanding: diluted	3,107	3,080	3,104	2,507
Net loss per share: basic	\$ (0.62)	\$ (0.31)	\$ (1.24)	\$ (0.85)
Net loss per share: diluted	\$ (0.62)	\$ (0.31)	\$ (1.24)	\$ (0.85)

### ***Liquidity and Capital Resources***

We reported a net loss of \$1,939,000 and \$3,843,000 for the three and nine months ended December 31, 2022. At December 31, 2022 and March 31, 2022, our accumulated deficit amounted to \$188,206,000 and \$184,363,000, respectively. As of December 31, 2022, we had cash and cash equivalents of \$2,634,000 compared to \$8,529,000 on December 31, 2021. Since our inception, substantially all of our operations have been financed through sales of equity securities. Other sources of financing that we have used to date include our revenues, royalty payments from licensing our products, as well as various loans and the sale of certain assets to Invekra, Petagon, and Microsafe.

The following table presents a summary of our consolidated cash flows for operating, investing and financing activities for the nine months ended December 31, 2022 and 2021 as well as balances of cash and cash equivalents and working capital:

<i>(In thousands)</i>	Nine Months Ended December 31,	
	2022	2021
Net cash provided by (used in):		
Operating activities	\$ (3,711)	\$ (2,853)
Investing activities	(176)	(38)
Financing activities	(883)	7,174
Effect of exchange rates on cash	8	26
Net change in cash and cash equivalents	(4,762)	4,309
Cash and cash equivalents, beginning of the period	\$ 7,396	\$ 4,220
Cash and cash equivalents, end of the period	\$ 2,634	\$ 8,529
Working capital <sup>(1)</sup> , end of period	\$ 7,298	\$ 13,824

(1) Defined as current assets minus current liabilities

Net cash used by operating activities during the nine months ended December 31, 2022 was \$3,711,000, primarily due to a net loss of \$3,843,000, and a decrease in deferred revenue of \$1,204,000 offset by \$569,000 of stock based compensation.

Net cash used by operating activities during the nine months ended December 31, 2021, was \$2,853,000, primarily due to a net loss of \$2,142,000 and forgiveness on PPP loans of \$723,000.

Net cash used by investing activities was \$176,000 for the nine months ended December 31, 2022, primarily related to long term deposits and purchases of equipment.

Net cash used by investing activities was \$38,000 for the nine months ended December 31, 2021, primarily related to purchases of equipment.

Net cash used by financing activities was \$883,000 for the nine months ended December 31, 2022, primarily due to principal payments on long-term debt of \$674,000 and payments of PPP loan of \$120,000.

Net cash provided by financing activities was \$7,174,000 for the nine months ended December 31, 2021, primarily related to the proceeds from issuance of common stock of \$7,554,000, and partially offset by payments on long term debt.

We expect revenues to fluctuate and may incur losses in the foreseeable future and may need to raise additional capital to pursue our product development initiatives, to penetrate markets for the sale of our products and continue as a going concern. We cannot provide any assurances that we will be able to raise additional capital.

Management believes that we have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, we cannot provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the economic climate in the U.S. deteriorates, our ability to raise additional capital could be negatively impacted. If we are unable to secure additional capital, we may be required to take additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations and meet our obligations. These measures could cause significant delays in our continued efforts to commercialize our products, which is critical to the realization of our business plan and our future operations. These matters raise substantial doubt about our ability to continue as a going concern.



## **Material Trends and Uncertainties**

We are exposed to risk from decline in foreign currency for both the euro and the Mexico peso versus the U.S. dollar. Most recently there has been a sharp decline in the euro versus the U.S. dollar which has impacted our financial results.

As we have previously discussed in our annual report on Form 10-K filed with the SEC on July 13, 2022, we face a substantial Mexico tax liability, intercompany debt, unpaid technical assistance charges and accrued interest. These amounts are not due until 2027. At this time, management believes there are sufficient assets on the balance sheet to more than cover any tax obligation without interrupting our operations or business. We have engaged tax professionals to review all options to limit our exposure to these amounts and to proceed in a manner that is most advantageous to us.

As the pandemic continues to impact economies worldwide, we are closely watching inflation, increased volatility within financial markets, shipping costs, supply chain issues and labor costs. At this time, we have seen an increase in shipping costs however, the overall impact of these issues has been minimal. The potential impact to our business operations, customer demand and supply chain due to increased shipping costs may ultimately impact sales. We continue to evaluate our end-to-end supply chain and assess opportunities to refine the impact on sales. Currently, our customers pay for most of the shipping expenses necessary to get products to their home countries, including increased shipping costs, if any. We have not yet faced labor shortages however it is possible we may have difficulties retaining and finding qualified employees in a tight labor market in the future. Furthermore, overall inflation tendencies may put pressure on our product pricing and/or costs.

We also closely monitor overall economic conditions, consumer sentiment and the prospect of a recession in the United States which may impact our financial results.

On August 16, 2022, the U.S. government enacted the Inflation Reduction Act. The Inflation Reduction Act introduced a new 15% corporate minimum tax, based on adjusted financial statement income of certain large corporations. Applicable corporations would be allowed to claim a credit for the minimum tax paid against regular tax in future years. The minimum tax impact applies starting in 2023. The Inflation Reduction Act also includes an excise tax that would impose a 1% surcharge on stock repurchases. This excise tax was effective January 1, 2023.

The Company is currently evaluating the effect of the Inflation Reduction Act on its consolidated financial statements.

## **Use of Estimates**

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance related to our deferred tax assets, valuation of equity and derivative instruments, debt discounts, valuation of investments and the estimated amortization periods of upfront product licensing fees received from customers.

## **Off-Balance Sheet Transactions**

We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

As a smaller reporting company, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information required by this Item.

**Item 4. Controls and Procedures****Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of our most recent fiscal quarter. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of December 31, 2022. We have determined that there were inadequate spreadsheet controls, a lack of separation of duties with preparation and review of the reported numbers, and inadequate analysis of revenue reporting among other things that led to a restatement of results for the quarter ended June 30, 2020. These weaknesses also lead to correction of results at the time of filing our annual report on Form 10-K for the year ended March 31, 2021.

Notwithstanding the material weaknesses, management believes the consolidated financial statements included in this Quarterly Report on Form 10-Q present fairly, in all material respects, our financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. generally accepted accounting principles.

**Management's Remediation Measures**

Management, with oversight from the Audit Committee of our Board of Directors, is actively engaged in remediation efforts to address the material weaknesses identified in the management's evaluation of internal controls and procedures. Management has taken a number of actions to remediate the material weaknesses described above, including the following:

- Improved monitoring and risk assessment activities to address these control deficiencies.
- Hired a new full time Chief Financial Officer in October 2022.
- Separated the preparation of the financial reports from review of the financial reports.
- Implemented additional process-level controls over revenue recognition of new contracts.
- Developed and delivered further internal controls training to individuals associated with these control deficiencies and enhanced training provided to all personnel who have financial reporting or internal control responsibilities in these areas. The training includes a review of individual roles and responsibilities related to internal controls and of proper oversight and reemphasizes the importance of completing the control procedures.
- Did a detailed review of income taxes and our intercompany agreements which uncovered the fact that we should be accruing withholding taxes that will be paid to Mexico when intercompany interest and Technical Assistance payments are made to Mexico from the United States, and that we will not be eligible for a tax credit in the United States because of our Net Operating Loss positions.

These improvements are targeted at strengthening our internal control over financial reporting and remediating the material weaknesses. We remain committed to an effective internal control environment, and management believes that these actions and the improvements management expects to achieve as a result will effectively remediate the material weaknesses. However, the material weaknesses in our internal control over financial reporting will not be considered remediated until the controls operate for a sufficient period of time and management has concluded through testing that these controls operate effectively. As of the date of filing this Quarterly Report on Form 10-Q, management is in the process of testing and evaluating these additional controls to determine whether they are operating effectively. As announced in July 2022, we have closed our Woodstock, Georgia office and consolidated operations in Boulder, Colorado. Our former Chief Financial Officer resigned but assisted with this transition through November 18, 2022. Our current Chief Financial Officer began October 3, 2022, and we have hired appropriate accounting staff in Colorado to establish effective internal controls and processes.

#### **Changes in Internal Control over Financial Reporting**

There were no changes in our internal control over financial reporting during the three months ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We have not finished our testing of our remediated controls, sufficient time has not elapsed to make the determination that these controls are operating effectively and changes to internal controls are currently being implemented in connection with the relocation of our finance team to Boulder, Colorado.

## **PART II - OTHER INFORMATION**

### **Item 1. Legal Proceedings**

On occasion, we may be involved in legal matters arising in the ordinary course of our business including matters involving proprietary technology. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which we are or could become involved in litigation may have a material adverse effect on our business, financial condition or results of comprehensive loss.

### **Item 1A. Risk Factors**

There have been no material changes from risk factors previously disclosed in our annual report on Form 10-K for the fiscal year ended March 31, 2022, as filed with the SEC July 13, 2022.

### **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

We did not issue any unregistered securities during the quarter ended December 31, 2022 and through February 10, 2023.

### **Item 3. Default Upon Senior Securities**

We did not default upon any senior securities during the quarter ended December 31, 2022.

### **Item 4. Mine Safety Disclosures**

Not applicable.

### **Item 5. Other Information**

None.

## Exhibit Index

Exhibit No.	Description
3.1	<a href="#"><u>Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., effective January 30, 2006</u></a> (included as exhibit 3.1 of the Company's Annual Report on Form 10-K filed June 20, 2007, and incorporated herein by reference).
3.2	<a href="#"><u>Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., effective October 22, 2008</u></a> (included as exhibit A in the Company's Definitive Proxy Statement on Schedule 14A filed July 21, 2008, and incorporated herein by reference).
3.4	<a href="#"><u>Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective March 29, 2013</u></a> (included as exhibit 3.1 to the Company's Current Report on Form 8-K filed March 22, 2013, and incorporated herein by reference).
3.5	<a href="#"><u>Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective December 4, 2014</u></a> (included as exhibit 3.1 to the Company's Current Report on Form 8-K filed December 8, 2014, and incorporated herein by reference).
3.6	<a href="#"><u>Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective October 22, 2015</u></a> (included as exhibit 3.1 to the Company's Current Report on Form 8-K filed October 27, 2015, and incorporated herein by reference).
3.7	<a href="#"><u>Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective June 24, 2016</u></a> (included as exhibit 3.1 to the Company's Current Report on Form 8-K filed June 28, 2016, and incorporated herein by reference).
3.8	<a href="#"><u>Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective December 6, 2016</u></a> (included as exhibit 3.1 to the Company's Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).
3.9	<a href="#"><u>Amended and Restated Bylaws, as amended, of Sonoma Pharmaceuticals, Inc., effective December 6, 2016</u></a> (included as exhibit 3.2 to the Company's Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).
3.10	<a href="#"><u>Certificate of Designation of Preferences, Rights and Limitations of Series A 0% Convertible Preferred Stock, filed with the Delaware Secretary of State on April 24, 2012</u></a> (included as exhibit 4.2 to the Company's Current Report on Form 8-K, filed April 25, 2012, and incorporated herein by reference).
3.11	<a href="#"><u>Certificate of Designation of Series B Preferred Stock, effective October 18, 2016</u></a> (included as exhibit 3.1 to the Company's Current Report on Form 8-K filed October 21, 2016, and incorporated herein by references).
3.12	<a href="#"><u>Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective June 19, 2019</u></a> (included as exhibit 3.1 to the Company's Current Report on Form 8-K filed June 19, 2019, and incorporated herein by reference).
4.1	<a href="#"><u>Specimen Common Stock Certificate</u></a> (included as exhibit 4.1 to the Company's Annual Report on Form 10-K filed June 28, 2017, and incorporated herein by reference).
4.2	<a href="#"><u>Section 382 Rights Agreement, dated as of October 18, 2016, between Oculus Innovative Sciences, Inc. and Computershare Inc., which includes the Form of Certificate of Designation of Series B Preferred Stock as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Stock as Exhibit C</u></a> (included as exhibit 4.1 to the Company's Current Report on Form 8-K filed October 21, 2016, and incorporated herein by reference).
4.3	<a href="#"><u>Form of Placement Agent Warrant granted to Dawson James Securities, Inc. and The Benchmark Company, LLC in connection with the March 2, 2018 public offering, dated March 6, 2018</u></a> (included as exhibit 4.1 to the Company's Current Report on Form 8-K filed March 6, 2018, and incorporated herein by reference).
4.4	<a href="#"><u>Form of Placement Agent Warrant granted to Dawson James Securities, Inc. in connection with the November 2019 public offering</u></a> (included as exhibit 4.1 to the Company's Current Report on Form 8-K filed on November 29, 2019, and incorporated herein by reference).

10.1	<a href="#"><u>Form of Indemnification Agreement between Oculus Innovative Sciences, Inc. and its officers and directors</u></a> (included as exhibit 10.1 to the Company's Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
10.2	<a href="#"><u>Office Lease Agreement, dated May 18, 2006, between Oculus Technologies of Mexico, S.A. de C.V. and Antonio Sergio Arturo Fernandez Valenzuela (translated from Spanish)</u></a> (included as exhibit 10.10 to the Company's Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
10.3	<a href="#"><u>Office Lease Agreement, dated July 2003, between Oculus Innovative Sciences, B.V. and Artikona Holding B.V. (translated from Dutch)</u></a> (included as exhibit 10.11 to the Company's Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
10.4	<a href="#"><u>Form of Director Agreement</u></a> (included as exhibit 10.20 to the Company's Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
10.5	<a href="#"><u>Amended and Restated Oculus Innovative Sciences, Inc. 2006 Stock Incentive Plan and related form stock option plan agreements</u></a> (included as exhibit 10.2 to the Company's Current Report on Form 8-K filed May 2, 2007, and incorporated herein by reference).
10.6	<a href="#"><u>Amendment to Office Lease Agreement, effective February 15, 2008, by and between Oculus Innovative Sciences Netherlands B.V. and Artikona Holding B.V. (translated from Dutch)</u></a> (included as exhibit 10.44 to the Company's Annual Report on Form 10-K filed June 13, 2008, and incorporated herein by reference).
10.7	<a href="#"><u>Oculus Innovative Sciences, Inc. 2011 Stock Incentive Plan</u></a> (included as exhibit A in the Company's Definitive Proxy Statement on Schedule 14A filed July 29, 2011, and incorporated herein by reference).
10.8†	<a href="#"><u>Exclusive Sales and Distribution Agreement, dated November 6, 2015, by and between Oculus Innovative Sciences, Inc. and Manna Pro Products, LLC</u></a> (included as exhibit 10.1 to the Company's 8-K filed March 23, 2016 and incorporated herein by reference).
10.9†	<a href="#"><u>Asset Purchase Agreement dated October 27, 2016, between Oculus Innovative Sciences, Inc. and Invektra, S.A.P.I de C.V.</u></a> (included as Exhibit 10.1 to the Company's Current Report on Form 8-K filed October 31, 2016, and incorporated herein by reference).
10.10†	<a href="#"><u>Amendment Agreement to Acquisition Option dated October 27, 2016, by and between More Pharma Corporation S. de R.L. de C.V. and Oculus Technologies of Mexico, S.A. de C.V.</u></a> (included as Exhibit 10.2 to the Company's Current Report on Form 8-K filed October 31, 2016, and incorporated herein by reference).
10.11	<a href="#"><u>2016 Equity Incentive Plan</u></a> (included as exhibit A in the Company's Definitive Proxy Statement on Schedule 14A filed July 29, 2016, and incorporated herein by reference).
10.12	<a href="#"><u>Securities Purchase Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and Montreux Equity Partners V, L.P., dated March 1, 2018</u></a> (included as exhibit 10.2 to the Company's Current Report on Form 8-K filed on March 6, 2018, and incorporated herein by reference).
10.13†	<a href="#"><u>Exclusive License and Distribution Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and EMS S.A., dated June 4, 2018</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on June 5, 2018, and incorporated herein by reference).
10.14	<a href="#"><u>Warrant Agency Agreement entered into by and among Sonoma Pharmaceuticals, Inc., Computershare, Inc. and Computershare Trust Company, N.A., dated November 21, 2018</u></a> (included as exhibit 10.2 to the Company's Current Report on Form 8-K filed on November 21, 2018, and incorporated herein by reference).
10.154+	<a href="#"><u>Asset Purchase Agreement dated May 14, 2019, between Sonoma Pharmaceuticals, Inc. and Petagon, Ltd.</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on May 22, 2019, and incorporated herein by reference).
10.164+	<a href="#"><u>Asset Purchase Agreement dated February 21, 2020, between Sonoma Pharmaceuticals, Inc. and MicroSafe Group, DMCC</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on February 27, 2020, and incorporated herein by reference.)
10.174+	<a href="#"><u>License, Distribution and Supply Agreement by and between Sonoma Pharmaceuticals, Inc. and Brill International, S.L. dated May 19, 2020</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on May 26, 2020, and incorporated herein by reference.)

10.18	<a href="#"><u>Consulting Agreement between the Company and Dr. Robert Northey, dated May 30, 2020</u></a> (included as exhibit 10.2 to the Company's Current Report on Form 8-K filed on June 4, 2020, and incorporated herein by reference.)
10.19+4	<a href="#"><u>Asset Purchase Agreement between the Company and Infinity Labs SD, Inc., dated June 24, 2020</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on June 30, 2020, and incorporated herein by reference.)
10.20+	Woodstock Lease Agreement between the Company and Fowler Crossing Partners, LP, dated October 1, 2018.
10.214	<a href="#"><u>Licensing Agreement between Sonoma Pharmaceuticals, Inc. and MicroSafe Group, effective July 27, 2020</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on August 6, 2020, and incorporated herein by reference).
10.224	<a href="#"><u>Licensing and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Gabriel Science, LLC, effective December 14, 2020</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on December 17, 2020, and incorporated herein by reference).
10.234	<a href="#"><u>Exclusive Supply and Distribution Agreement between the Company and EMC Pharma, LLC, dated March 26, 2021</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on March 31, 2021, and incorporated herein by reference).
10.24	<a href="#"><u>Amended and Restated Employment Agreement by and between the Company and Amy Trombly, dated July 22, 2022</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on July 22, 2022, and incorporated herein by reference).
10.25	<a href="#"><u>Employment Agreement by and between the Company and Jerry Dvonch, dated July 1, 2021</u></a> (included as exhibit 10.2 to the Company's Current Report on Form 8-K filed on July 6, 2021, and incorporated herein by reference).
10.26	<a href="#"><u>Amended and Restated Employment Agreement by and between the Company and Bruce Thornton, dated July 22, 2022</u></a> (included as exhibit 10.2 to the Company's Current Report on Form 8-K filed on July 22, 2022, and incorporated herein by reference).
10.27	<a href="#"><u>Offer letter to Chad White dated September 8, 2022</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on October 7, 2022, and incorporated herein by reference).
10.28	<a href="#"><u>At-The-Market Offering Agreement, by and between the Company and H.C. Wainwright &amp; Co., LLC, dated July 30, 2021</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on July 30, 2021, and incorporated herein by reference).
10.29	<a href="#"><u>2021 Equity Incentive Plan</u></a> (included as appendix on the Company's proxy statement filed on July 29, 2021 and incorporated herein by reference).
10.30+4	<a href="#"><u>Exclusive License and Distribution Agreement between the Company and Dyamed Biotech Pte Ltd., dated November 4, 2021</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on November 9, 2021, and incorporated herein by reference).
10.31+4	<a href="#"><u>Non-Exclusive Distribution and Supply Agreement between the Company and Salus Medical, LLC dated January 19, 2022</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on January 20, 2022, and incorporated herein by reference).
10.32+4	<a href="#"><u>Exclusive License and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Anlicare International dated January 18, 2022</u></a> (included as exhibit 10.2 to the Company's Current Report on Form 8-K filed on January 20, 2022, and incorporated herein by reference).
10.33	<a href="#"><u>At-The-Market Offering Agreement, by and between the Company and Ladenburg Thalmann &amp; Co. Inc., dated December 23, 2022</u></a> (included as exhibit 1.1 to the Company's Current Report on Form 8-K filed on December 23, 2022, and incorporated herein by reference).
10.34	<a href="#"><u>Sonoma Pharmaceuticals, Inc. Non-Employee Director Compensation Program and Stock Ownership Guidelines, revised by the Board of Directors on December 29, 2022</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on December 30, 2022, and incorporated herein by reference).

10.35+4	<a href="#"><u>Exclusive Distribution and Supply Agreement, dated January 26, 2023, by and between Sonoma Pharmaceuticals, Inc. and Daewoong Pharmaceutical Co., Ltd.</u></a> (included as exhibit 10.1 to the Company's Current Report on Form 8-K filed on January 31, 2023, and incorporated herein by reference).
14.1	<a href="#"><u>Code of Business Conduct</u></a> (included as Exhibit 14.1 to the Company's Current Report on Form 8-K filed on January 23, 2017, and incorporated herein by reference).
21.1	<a href="#"><u>List of Subsidiaries</u></a> (included as Exhibit 21.1 to the Company's Annual Report on Form 10-K on June 28, 2017, and incorporated herein by reference).
31.1*	<a href="#"><u>Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u></a>
31.2*	<a href="#"><u>Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u></a>
32.1*	<a href="#"><u>Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u></a>
101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted in inline XBRL, and included in exhibit 101).

\* Filed herewith.

† Confidential treatment has been granted with respect to certain portions of this agreement.

‡ Certain portions of the exhibit have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC upon request.

+ The schedules to the exhibit have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish copies of any such schedules to the SEC upon request.

Copies of above exhibits not contained herein are available to any stockholder, upon payment of a reasonable per page fee, upon written request to: Chief Financial Officer, Sonoma Pharmaceuticals, Inc., 5445 Conestoga Court, Suite 150, Boulder, Colorado 80301.



## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: February 14, 2023

By: /s/ Amy Trombly  
Amy Trombly  
President and Chief Executive Officer, (Principal Executive Officer)

Date: February 14, 2023

/s/ Chad White  
Chad White  
Chief Financial Officer  
(Principal Financial and  
Principal Accounting Officer)

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO  
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002  
(18 U.S.C. SECTION 1350)**

I, Amy Trombly, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sonoma Pharmaceuticals, Inc. for the quarter ended December 31, 2022;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 14, 2023

By: /s/ Amy Trombly  
Amy Trombly  
Chief Executive Officer  
(Principal Executive Officer)

**CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO  
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002  
(18 U.S.C. SECTION 1350)**

I, Chad White, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sonoma Pharmaceuticals, Inc. for the quarter ended December 31, 2022;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 14, 2023

By: /s/ Chad White  
Chad White  
Chief Financial Officer  
(Principal Financial Officer and Principal Accounting Officer)

**CERTIFICATION PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  
(18 U.S.C. SECTION 1350)**

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officers of Sonoma Pharmaceuticals, Inc., a Delaware corporation (the "Company"), do hereby certify, to such officers' knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended December 31, 2022 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 14, 2023

By: /s/ Amy Trombly  
Amy Trombly  
Chief Executive Officer  
(Principal Executive Officer)

Date: February 14, 2023

By: /s/ Chad White  
Chad White  
Chief Financial Officer  
(Principal Financial Officer and Principal Accounting Officer)